• FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • FTSE 250

    22,659.42
    -20.22 (-0.09%)
     
  • AIM

    1,231.09
    +8.94 (+0.73%)
     
  • GBP/EUR

    1.1698
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.3972
    +0.0025 (+0.1802%)
     
  • BTC-GBP

    24,077.66
    +862.46 (+3.72%)
     
  • CMC Crypto 200

    807.37
    -2.82 (-0.35%)
     
  • S&P 500

    4,249.51
    +3.07 (+0.07%)
     
  • DOW

    33,928.25
    -17.33 (-0.05%)
     
  • CRUDE OIL

    73.59
    +0.74 (+1.02%)
     
  • GOLD FUTURES

    1,787.50
    +10.10 (+0.57%)
     
  • NIKKEI 225

    28,874.89
    -9.24 (-0.03%)
     
  • HANG SENG

    28,817.07
    +507.31 (+1.79%)
     
  • DAX

    15,456.39
    -179.94 (-1.15%)
     
  • CAC 40

    6,551.07
    -60.43 (-0.91%)
     

LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:30 a.m. ET.

The presentation will be webcast and can be accessed from the investor relations section of the company's website at www.lavatherapeutics.com.

About LAVA

LAVA Therapeutics N.V. is a clinical stage biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematological malignancies based on its proprietary platform. The company’s innovative approach utilizes bispecific antibodies engineered to selectively kill cancer cells and induce gamma-delta T cell-mediated immunity through activation of Vγ9Vδ2 T cells upon cross-linking to tumor associated antigens. A Phase 1/2a clinical study evaluating LAVA-051 in patients with certain hematologic malignancies is anticipated to generate top line clinical data in the first half of 2022. The Company expects to initiate a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer in the second half of 2021. For more information, please visit www.lavatherapeutics.com.

Contact
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting